Canada: Reduced Requirements for Subsequent Entry Biologics (SEBs) in Canada: Health Canada Releases Final Guidance Document

Health Canada recently released the final version of its guidance document " Guidance for Sponsors: Information and Submission Requirements for Subsequent Entry Biologics (SEBs) ." The document provides guidance to sponsors on how to satisfy the information and regulatory requirements under the Food and Drugs Act and regulations for approval of SEBs in Canada. At the same time, Health Canada also updated the Data Protection and Patented Medicines (Notice of Compliance) (PM(NOC)) guidelines to address certain issues specific to SEBs.

The significance of the new and updated guidelines is that they:

  1. provide for a somewhat abbreviated submission package for SEBs, by accepting a reduced non-clinical and clinical data package;
  2. state that SEBs will not qualify as an "innovative drug" for data protection;
  3. state that SEBs will be subject to the submission filing and approval restrictions of the data protection provisions if their submissions rely on another innovative product that has been afforded data protection, as per regulations; and
  4. state that SEBs will be subject to section 5 of the PM(NOC) Regulations if they make "a direct or indirect comparison with, or reference to, another drug."

Biologics (or biological medicines) are manufactured from or through the use of animals or microorganisms, unlike pharmaceutical drugs which are synthesized by traditional chemical methods. Biologics are drugs listed in Schedule D to the Food and Drugs Act and include products such as immunizing agents and drugs obtained by recombinant DNA procedures.

An SEB, known as a "biosimilar" in Europe and "follow-on biologic" in the US, is defined by Health Canada as a "biologic drug that enters the market subsequent to a version previously authorized in Canada, and with demonstrated similarity to a reference biologic drug."

In the guidelines, Health Canada affirms that the authorization of an SEB is not a declaration of pharmaceutical and/or therapeutic equivalence to the reference biologic drug. An SEB is not a "generic" biologic.

The demonstration of "similarity" means that:

  • the existing knowledge of both products is sufficient to predict that any differences in quality attributes should have no impact upon safety or efficacy of the SEB; and
  • non-clinical and clinical data previously generated with the reference biologic drug can be used for the SEB.

This implies that the SEB and the reference biologic drug product are not necessarily substitutable or interchangeable.

While the guidelines provide for an abbreviated approval process for SEBs, the sponsor will still need to file a new drug submission (NDS) for market approval. In the NDS, the sponsor must clearly identify, and demonstrate similarity to, a previously Canadian-approved biologic drug. Similarity is determined on the basis of analytical testing, biological assays and, to a lesser degree, non-clinical and clinical data. In certain circumstances, a manufacturer may be able to use a foreign reference product not authorized for sale in Canada to demonstrate similarity. The submission in that case should clearly explain the link between the reference product and the innovator product approved in Canada.

The guidelines set out the requirements for clinical trial applications and post-marketing. They also indicate that an SEB should not be used as a reference biologic drug for future SEB submissions.

Sponsors of an SEB will not be able to utilize the product monograph (PM) of the reference biologic drug in its entirety as that of its own product. However, the PM for SEBs will include tables showing the results of the comparisons between the SEB and reference biologic drug.

SEBs will also be subject to the PM(NOC) Regulations and the data protection provisions of the Food and Drug Regulations, as well as their respective guidance documents, " Guidance Document: Patented Medicines (Notice of Compliance) Regulations " and " Guidance Document: Data Protection under C.08.004.1 of the Food and Drug Regulations ." These guidance documents were amended concurrently with the SEB guidelines.

Under the PM(NOC) Regulations, SEBs that made "a direct or indirect comparison with, or reference to" a previously approved drug in its drug submission will be subject to section 5 of those regulations. Accordingly, a manufacturer of such an SEB will be required to either accept that market approval for the SEB will be delayed until the patents on the Patent Register expire or file a notice of allegation. Thus, if a first drug has a patent listed on the Health Canada Patent Register, the SEB will not receive market approval until the patents have expired, or the SEB manufacturer can show the patent is invalid, improperly listed or not infringed.

Under the Food and Drug Regulations data protection provisions, SEBs will not qualify as an "innovative drug" for data protection. Thus manufacturers of SEBs cannot benefit from data protection. On the other hand, SEBs will be subject to the drug submission filing and approval restrictions of those provisions, if their submissions rely on another innovative product that has been afforded data protection. That is, sponsors will not be able to file a drug submission for an SEB on the basis of a direct or indirect comparison to an "innovative drug" until six years after the notice of compliance (NOC) for the innovative drug was issued. Furthermore, sponsors will not be granted an NOC until eight years from the date of the issuance of the first NOC for the innovative drug. This way, independent of any patent protection, the innovator gets eight years of exclusivity. Note these time lines can be extended by six months if pediatric studies are conducted in accordance with the prescribed requirements.

McCarthy Tétrault Notes

Before the guidelines were finalized, Health Canada approved the first-ever SEB. Following similar actions taken by the European Medical Agency and the US Food and Drug Administration, Sandoz Canada received an NOC for its drug product Omnitrope", based on comparison with Genotropin®, a previously approved recombinant biotechnology drug product indicated for the treatment of growth hormone deficiency.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.